Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

NCT: NCT05632913 · RECRUITING

NCT IDNCT05632913
StatusRECRUITING
Start Date2023-07-01
Completion2027-02
SponsorAlpha Tau Medical LTD. (INDUSTRY)
First posted
Last updated

Brief Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .

Frequently Asked Questions

What is Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer is a clinical trial registered under NCT05632913. Current status: RECRUITING.

What is the status of NCT05632913?

The current status of NCT05632913 (Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer) is: RECRUITING.

When did Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer start?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer started on 2023-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑